T.G. SAKOVETS

Kazan State Medical University, 49 Butlerov Str., Kazan, Russian Federation, 420012

Sakovets T.G. ― Cand. Med. Sc., Assistant of the Department of Neurology and Rehabilitation, tel. +7-909-307-94-77, e-mail: tsakovets@yandex.ru

Systemic vasculitis is a heterogeneous group of diseases characterized by inflammation and damage to blood vessels of various calibers. This nosology is divided into separate (primary) diseases and those associated with other diseases, exposure to drugs or toxic agents (secondary vasculitis). In all these cases, primary and secondary systemic vasculitic neuropathy may be identified. If the symptoms of vasculitis are limited to symptomatic lesions of nerves and muscles, the nosology is defined as non-systemic vasculitis. Treatment includes corticosteroids, cytotoxic agents, intravenous immunoglobulins, plasma exchange. It requires a multidisciplinary approach with the participation of neurologists, rheumatologists, physiotherapists, to evaluate the degree of organic damage, the nature of systemic vasculitis, the presence of a viral infection, and the clinical response to treatment of vasculitis neuropathy. As neurologists play an important role in the diagnosis and treatment of patients with vasculitis neuropathy, they should be informed of the classification of this nosology, schemes of treatment, variants of the course of neuropathic disorders in patients with rheumatologic profile. It is necessary to study the promising new methods of treatment for vasculitis neuropathy.

Key words: systemic vasculitis, non-systemic vasculitis, treatment of the vasculitis neuropathy, vasculitic neuropathy.

REFERENCES

1. Baratta J.M., Dyck P.J., Brand P. et al. Vasculitic neuropathy following exposure to minocycline. Neurol. Neuroimmunol. Neuroinflamm, 2016, vol. 3, no. 1, pp. 180.
2. Gwathmey K.G., Burns T.M., Collins M.P. et al. Vasculitic neuropathies. Lancet Neurol, 2014, no. 13, pp. 67-82.
3. Blaes F. Diagnosis and therapeutic options for peripheral vasculitic neuropathy. Ther. Adv. Musculoskelet. Dis, 2015, vol. 7, no. 2, pp. 45-55.
4. Vrancken A.F., Hughes R.A., Said G. et al. Cochrane Database Syst. Rev, 2007, no. 1, CD006050.
5. Fanouriakis A., Kougkas N., Vassilopoulos D. et al. Rituximab for eosinophilic granulomatosis with polyangiitis with severe vasculitic neuropathy: Case report and review of current clinical evidence. Seminars in Arthritis and Rheumatism, 2015, no. 45, pp. 60-66.
6. Naddaf E., Dyck P.J. Vasculitic neuropathies. Curr. Treat. Options Neurol, 2015, vol. 17, no.10, p. 374.
7. Bradley W.G., Verma A. Painful vasculitic neuropathy in HIV-1 infection: relief of pain with prednisone therapy. Neurology, 1996, vol. 47, no. 6, pp. 1446-1451.
8. Üçeyler N., Geng A., Reiners K. et al. Non-systemic vasculitic neuropathy: single-center follow-up of 60 patients. J. Neurol, 2015, vol. 262, no. 9, pp. 2092-2100.
9. Collins M.P., Periquet M.I., Mendell J.R. et al. Nonsystemic vasculitic neuropathy: insights from a clinical cohort. Neurology, 2003, vol. 61, no. 5, pp. 623-630.
10. Kinter J., Broglio L., Steck A.J. et al. Gene expression profiling in nerve biopsy of vasculitic neuropathy. Journal of Neuroimmunology, 2010, 225, pp. 184-189.